Introduction {#s0010}
============

Respiratory tract infections are common, and a major cause of morbidity and mortality around the world. Viruses are responsible for about 90% of upper respiratory tract infections, and about 30% of lower respiratory tract infections. Each respiratory syndrome can be caused by a number of different viruses, and each individual virus can result in several different clinical presentations.

Several respiratory tract infections per year are common, due to the easy spread of a large variety or organisms via aerosol and droplet spread, as well as fomites (e.g. through contact with objects on which other people may have, for example, sneezed).

Spectrum of disease {#s0015}
===================

[Table 1](#t0010){ref-type="table"} lists the common conditions, and associated viruses. For individual viruses see the relevant chapter.Table 1Common conditions and associated virusesConditionCommon viral causesOther virusesRhinitis/common coldRhinovirusesCoronavirusesAdenovirusesEnterovirusesInfluenza virusesHuman metapneumovirus ParainfluenzaRespiratory syncytial virus (RSV)PharyngitisAdenovirusesEnteroviruses -- Coxsackie AInfluenza virusesParainfluenzaHerpesviruses -- herpes simplex virus (HSV), Epstein-Barr virus (EBV), cytomegalovirus (CMV)RhinovirusesOtitis mediaAdenovirusesRhinovirusesCoronavirusesHuman metapneumovirusRSVLaryngotracheobronchitis (croup)CoronavirusesParainfluenzaRSVAdenovirusesInfluenzaHerpes simplexMeaslesBronchiolitisParainfluenzaRSVAdenovirusesCoronavirusesEnterovirusesHuman metapneumovirusHuman bocavirusRhinovirusesPneumoniaAdenovirusCMVInfluenzaParainfluenzaRSVHuman metapneumovirusHuman bocavirusCoronavirusesMeaslesVaricella

Individual causative agents: epidemiology, pathogenesis and clinical picture {#s0020}
============================================================================

Influenza viruses {#s0025}
-----------------

Influenza affects all ages and is a significant cause of respiratory disease worldwide. There are three types -- influenza A, B and C. Avian influenza, a potential threat to humans, is a type of influenza A. Influenza C causes a much milder clinical picture than the other viruses, while influenza A has caused several pandemics, the most well-known being the Spanish influenza of 1918. Annual epidemics occur in the winter season, and are currently caused by influenza B and influenza A H1N1 and H3N2.

The incubation period is 12--72 hours, followed by an abrupt onset of systemic symptoms. Infection is characterised by a cough, sore throat, fever and myalgia, although a wide range of presentations can occur, ranging from mild to severe with complications. Complications include secondary bacterial infections, viral pneumonia, myocarditis, myositis and Reye\'s syndrome.

Vaccination (see [Fig. 1](#f0010){ref-type="fig"} ) is one of the most important means to control the annual epidemics. Available vaccines are usually subunit vaccines (killed) but live attenuated vaccines are available in some countries. The indications and contraindications for the subunit vaccine are shown in [Table 2](#t0015){ref-type="table"} .Fig. 1Influenza vaccine pack.(Photo courtesy of sanofi pasteur.)Table 2Indications and contraindications for the influenza subunit vaccineIndicationsContraindicationsElderly -- over 50 yearsEgg allergyInfants -- 6 months--4 yearsAcute severe febrile illnessUnderlying medical conditions, such as diabetes, chronic lung or heart disease, obesityAge 6 months--18 years on chronic aspirin therapyNote: The indications for medical conditions, and the use in health-care workers exposed to these individuals with these conditions are considered to be contraindications for the use of the live attenuated vaccine.Women who will be pregnant during the influenza seasonImmunosuppressed persons (they need to be able to respond to the vaccination, however)Health-care workers, especially those working with those with other indicationsWorkplace -- avoidance of loss of productivityPersonal desire to avoid influenza infection

Antiviral drugs are available for the treatment of influenza and need to be started early in order to be effective. Amandatine and rimantadine, ion channel blockers, prevent influenza A from uncoating after it infects a cell. Oseltamivir and zanamivir are neuraminidase inhibitors that prevent release of new viruses from the cell surface. Resistance to these drugs is common.

Parainfluenza viruses {#s0030}
---------------------

There are four parainfluenza viruses, types 1--4, of which type 3 is the most common cause of the more severe disease. Parainfluenza 3 is seen throughout the year, with a peak in spring, while types 1 and 2 are seen in autumn.

The virus exhibits tropism for the ciliated epithelial cells lining larger airways. In infants infection usually presents as bronchiolitis, and in older children as croup. Pneumonia is rare in healthy children, but may be associated with underlying conditions such as prematurity or asthma. In adults, infection may present as bronchitis or rhinitis.

### Respiratory syncytial virus {#s0035}

Respiratory syncytial virus (RSV) is one of the main causes of hospitalisation of children in the first year of life in most parts of the world. By the age of 3 years most children have been infected.

The virus replicates in the respiratory mucosa, involving the lower respiratory tract. After an incubation period of 2--8 days, the clinical presentations include mild upper respiratory tract infection, otitis media, croup, pneumonia and bronchiolitis. Bronchiolitis presents with dyspnoea, tachypnoea, respiratory distress, wheezing and hyperinflation of the lung on X-ray. In premature infants and neonates, apnoea may be the only sign of infection. Symptoms usually resolve within a week, but if infants are sick for a longer period, they may require hospitalisation. In about 75% of those who develop RSV bronchiolitis, chronic wheezing can be present for a number of years. Infections in adults are less severe, although in the elderly and immunocompromised disease can be severe.

Treatment is usually supportive, with oxygenation, and bronchodilators and ventilation if necessary. Ribavirin can be used for treatment of severe cases. For prophylaxis, RSV immunoglobulin has been used, but palivizumab, a recombinant monoclonal antibody, has proved to be more effective. [Table 3](#t0020){ref-type="table"} gives a summary of the American Academy of Pediatrics guidelines for using palivizumab. Vaccines are not available, but are being investigated.Table 3Summary of the American Academy of Pediatrics guidelines for using palivizumabInfants \< 24 months old with chronic lung disease who have required medical therapy in the last 6 months.Infants \< 12 months old at the start of the respiratory syncytial virus (RSV) season, born before 28 weeks' gestation, and who have chronic lung disease.Infants \< 6 months old at the start of the RSV season, and who were born before 32 weeks' gestation.Infants \< 6 months old at the start of the RSV season, who were born between 32 and 35 weeks' gestation and have other risk factors, e.g. crowding at home, exposure to smokers, school-going siblings, one of twins.

Adenoviruses {#s0040}
============

Adenoviruses are believed to cause about 10% of respiratory illness worldwide, and can manifest as any of the most common respiratory presentations, although the common cold, pharyngitis, and otitis media are the most frequently seen. Pneumonia in young children is also of concern. No treatment exists, although ribavirin use has been reported. A vaccine for certain types is limited to use by military personnel and safety for children is of concern.

Rhinoviruses {#s0045}
------------

Rhinoviruses are found worldwide, and over 100 serotypes are known, which means that symptomatic infection with different strains often occurs. Spread is usually via nasal secretions. Rhinoviruses are the most common cause of the common cold, but can also cause other respiratory syndromes, especially in children with asthma, cystic fibrosis or other chronic lung diseases.

Coronaviruses {#s0050}
-------------

Five human coronaviruses are known; four circulate worldwide and affect all age groups, and the fifth, the cause of SARS no longer circulates. See the chapter on coronaviruses for more detail.

Cytomegalovirus {#s0055}
---------------

Cytomegalovirus (CMV) is seen worldwide, amongst all ages. Pneumonitis is found mainly in immunocompromised adults and in premature and immunocompromised infants. Treatment is possible with gancyclovir, valgancyclovir, foscarnet and cidovofir.

Diagnosis of viral respiratory tract infections {#s0060}
===============================================

Diagnosis is best made on samples taken within the first 48 hours of infection, when the viral load in the respiratory tract is high. For lower respiratory tract infections, bronchial lavage, bronchioalveolar lavage and tracheal aspirates are the best specimens, although the viruses can sometimes be isolated from upper respiratory samples, such as nasal or throat swabs or nasopharyngeal aspirates. Samples should be sent to the laboratory as soon as possible with viral transport medium and storage at 4°C to preserve live virus.Serology: this is seldom used for purposes other than epidemiological surveillance.Isolation: rapid tests on respiratory samples are available for some viruses, with RSV and influenza testing used the most.Indirect immunofluorescence: on cells in respiratory samples this may also provide a rapid diagnosis.Cell culture: this is an important means of diagnosis using, e.g. vero and HeLa cells, which support the growth of most respiratory viruses. Many respiratory viruses grow better at 33°C instead of 37°C, as this corresponds better with the temperature of the respiratory tract.Molecular: polymerase chain reaction (PCR) is commonly used for metapneumovirus, bocavirus and the coronaviruses, but can be applied to all respiratory viruses. It is usually only available in certain laboratories.

Treatment {#s0065}
=========

Treatment is supportive for most respiratory viruses --symptomatic relief, with oxygenation and ventilation if necessary. Specific treatment for influenza and CMV is available.

Prevention {#s0070}
==========

For most respiratory pathogens, hygiene is important, i.e. in the prevention of aerosolised virus and contaminated surfaces. Live attenuated measles and varicella vaccines are available and for influenza both subunit (killed) and live attenuated vaccines are in use. Palivizumab is used to prevent RSV infection.Stop/Think▪What respiratory conditions are seen mainly in immunocompromised populations?▪Why will old specimens not produce optimal results?▪Why are children on chronic aspirin therapy given influenza vaccines? Key points▪Respiratory syncytial virus (RSV) infection can be prevented in high-risk infants using palivizumab.▪Fomites and aerosols should be prevented in order to limit spread of respiratory viruses.▪Influenza vaccination is a well-established method of protecting people against the annual influenza epidemic.
